J9183 Gemcitabine intravesical - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Gemcitabine intravesical

Brand Name:

Inlexzo

Strength:

225mg

HCPCS:

J9183

SEER*Rx Category:

Chemotherapy

Major Drug Class:

Antimetabolite

Minor Drug Class:

Pyrimidine Analog

Oral (Y/N):

No

FDA Approval Year:

2025

FDA Discontinuation Year:

CMS Effective Date:

March 18, 2026

CMS Discontinuation Date:

Status:

In Use